Carregant...
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor, which is United States Food and Drug Administration (FDA)-approved for chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. Ibrutinib is associated with atrial fibrillation and bleeding events. Our aim...
Guardat en:
| Publicat a: | Cureus |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cureus
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6063389/ https://ncbi.nlm.nih.gov/pubmed/30062075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2701 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|